Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749227 · ClinicalTrials.gov registry record · Phase 2
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02749227 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 4 participants.
The verdict
NCT02749227, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin (POMC) levels will reduce plasma POMC levels and this will be associated with a reduction in pituitary tumor size. Pasireotide LAR 40 mg will be administered monthly. Baseline and monthly visits on therapy will monitor plasma levels of POMC, other pituitary function, safety labs, glucose tolerance, physical examination, and visual fields. Pituitary magnetic resonance imaging (MRI) will be done at baseline, 6 months and 12 months of therapy. The eligible patient population will consist of adult patients with known silent corticotroph pituitary tumors and elevated plasma levels of POMC.
Interventions
- DRUG Pasireotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02749227
The ClinicalTrials.gov registry entry for NCT02749227 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide LAR is the first listed.
NCT02749227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02749227 about?
NCT02749227 is a clinical study titled "Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors". This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin (POMC) levels will r...
What is the current status of trial NCT02749227?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-07-10. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02749227?
The interventions under investigation include: Pasireotide LAR (DRUG).
Who is sponsoring clinical trial NCT02749227?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.